In my June 27, 2025 Accenture (ACN) post, I disclose my decision to initiate a position through a 'Core' account in the FFJ Portfolio. The company's share price has experienced weakness following this initial purchase. My long-term outlook for the company, however, remains positive. I have, therefore, been adding to my exposure and disclose increases [...]
When I last reviewed Cintas (CTAS) in this July 18, 2025 post, the company had recently released its FY2025 results and FY2026 guidance. Based on the currently available information and a $224.50 share price, I determined shares were too richly valued to warrant adding to my current exposure. Fast forward to September 4, 2025 and [...]
When I last reviewed S&P Global (SPGI) in my August 1, 2025 Wide Moat S&P Global’s Valuation Is Fair post, shares were trading at ~$546.50. The share price subsequently touched ~$579 on August 14. I did not expect to revisit SPGI until after its Investor Day on November 13, 2025. The company's share price, however, [...]
I last reviewed Copart (CPRT) in this May 28, 2025 post at which time the most current financial information was for Q3 and YTD2025. I, however, disclosed in my June 18 Copart’s Valuation Improves post, an additional increase in my CPRT exposure. With the release of Q4 and FY2025 results following the September 4 market [...]
Periodically, great companies temporarily fall out of favor with investors thus providing an investment opportunity. Intuitive Surgical (ISRG) is such a company. When I wrote my January 25, 2025 Beware Of Intuitive Surgical’s Valuation post, the share price had recently touched $616 before tracing back to $584. Despite the company's attractive long-term outlook, I viewed [...]
This FFJ Portfolio - August 2025 report is a high-level recap of my activity during the month. All monthly reports are accessible here. In recent posts I express my concern about what I perceive to be an environment in which many investors have little regard to the quality of the companies in which they invest. [...]
I last reviewed Agilent (A) in this May 30, 2025 post, at which time the most current financial information was for Q2 and YTD2025. With the release of Q3 and YTD2025 results and revised FY2025 outlook on August 27, I revisit this existing holding. Business Overview A has the following 3 reportable business segments: life [...]
When I last reviewed Veeva Systems (VEEV) in this May 29, 2025 post, I concluded that the company's valuation was no longer a bargain. At the time of that post, the most recent financial results were for Q1 2026. With the release of Q2 and YTD2026 results following the August 27 market close, let's revisit [...]
I last reviewed HEICO (HEI and HEI-a) in this May 30, 2025 post. At the time it had just released Q2 and YTD2025 results. With the release of Q3 and YTD2025 results following the August 25 market close, I revisit this existing holding to gauge HEI's valuation. There is no denying that HEI has richly [...]
I last reviewed Zoom Communications (ZM) in this May 27, 2025 post when the most current financial information was for Q1 2026. With the release of Q2 and YTD2026 results following the August 21, 2025 market close, I revisit this existing holding. Business Overview Part 1, Item 1 in ZM's FY2024 Form 10-K (see SEC [...]